<DOC>
	<DOCNO>NCT02909699</DOCNO>
	<brief_summary>This study investigate resveratrol ( phenol present red grape , wine peanut ) improve heart muscle function ability artery dilate response increase blood flow adult 65 year age old . Additionally , investigator look resveratrol improve function cell ( cellular house-keeping ) relate cardiovascular function .</brief_summary>
	<brief_title>Cardiovascular Health Older Adults Resveratrol ( CORE )</brief_title>
	<detailed_description>Age-related decline leave ventricular function endothelium-dependent vasodilation increase risk cardiovascular ( CV ) disease premature death older adult . Structural change arterial wall cardiac muscle indicate cause appear induce age-related oxidative stress inflammation reduce level autophagy , cellular `` house-keeping system '' . Pre-clinical study indicate resveratrol ( RSV ) , polyphenol present mostly grapes red wine , may improve leave ventricular cardiac muscle endothelial vasodilator function . Although , RSV show induce autophagy improve CV function animal , evidence effect CV system human lack , need clinical trial well understand effect RSV CV function human . Because old adult likely impairment central peripheral CV system , represent ideal population test effect RSV CV function . Therefore , central hypothesis RSV supplementation improve age-related left ventricular cardiac muscle function arterial vasodilation older adult ( &gt; 65 year ) . The participant undergo 90 day RSV treatment ( n=12 ) ( 1,000mg/day ) , ( n=12 ) ( 1,500mg/day ) placebo ( n=12 ) . Before intervention , investigator non-invasively investigate leave ventricular arterial vasodilator function . Additionally , investigator examine cardiac muscle damage inflammatory biomarkers blood autophagy endothelial function protein level skeletal muscle well understand molecular mechanism may underlie hypothesize beneficial effect RSV cardiovascular health older adult .</detailed_description>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>All criterion parent R01 ( IRB201400439 ) . Participants must meet inclusion criterion list order participate study . Ability understand study procedure comply entire length study ; Age 65 year old ; Moderately function ( i.e . summary score 4 12 Short Physical Performance Battery ) ; Body Mass Index ( BMI ) range : 2039.9 kg/m2 ; Willingness undergo test procedure . All candidate meet exclusion criterion list baseline disqualify study participation . NonEnglish speak individual . Failure provide inform consent ; Allergy/sensitivity grapes Japanese knotweed ; Current dietary supplementation grape seed extract ginko biloba ; Consumption ≥ 8 oz . red wine/dealcoholized red wine/red purple grape juice weekly ; Consumption dietary supplement contain resveratrol , quercetin , P. cuspidatum previous 90 day ; Active treatment cancer , stroke ( &lt; 6 month ) , peripheral vascular disease , coronary artery disease , myocardial infarction ( &lt; 6 month ) , congestive heart failure ( stage III IV ) , valvular heart disease , major psychiatric disease , severe anemia ( blood level Hemoglobin &lt; 8 g/dl ) , bleed disorder blood disorder , liver renal disease , diabetes , severe osteoarthritis , blindness deafness , fracture upper low extremity ( &lt; 6 month ) , upper low extremity amputation , Parkinson 's disease ; Cognitive impairment ( i.e . Mini Mental Status Exam ≤ 23 &amp; Clinical Dementia Rating ≥1 ) ; History significant head injury ; Physical activity ( i.e . running , bicycling , etc . ) ≥ 150 min/week ; Excessive alcohol use ( &gt; 2 drinks/day ) alcohol abuse ( &gt; 5 drinks/day male , &gt; 4 drinks/day female ) ; History substance abuse within past six month ; Mood disorder ( i.e . Center Epidemiological Studies Depression ( CESD ) ≥ 16 ) ; History tobacco use within past three year ; Resting heart rate &gt; 120 bpm screen visit ; Systolic blood pressure &gt; 160 mm Hg screen visit ; Diastolic blood pressure &gt; 90 mm Hg screen visit ; Fasting glucose ≥ 126 mg/dL screen visit ; Abnormalities blood chemistry parameter , define blood chemistry marker outside healthy range ) determine study physician Current use anabolic treatment ( e.g . growth hormone testosterone ) , anticholinesterase inhibitor ( e.g . Aricept ) , hormone replacement ( e.g . Estrogen ) , anticoagulant therapy ( note : aspirin antiplatelet use ( ≤ 81mg/day ) permit ) use antiinflammatory medication 3 time per week . ; Participation another nonobservational clinical trial , receive investigational product within 30 day prior screening/enrollment ; Refuse refrain CoQ10 alphalipoic acid enrol study . Temporary Exclusion Criteria A person meeting follow temporary exclusion criterion time screen would enrol may rescreened later date . A period 4 week minimum amount time require rescreening follow condition do . Recent bacterial/viral infection ( &lt; 2 week ) ; Acute febrile illness past 2 month ; High blood pressure ( i.e . ≥ 140/90 mm Hg ≤ 160/90 ) screen visit ; Major surgery hip/knee replacement ( &lt; 6 month ) ;</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>